Detalles de la búsqueda
1.
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
N Engl J Med;
385(23): 2123-2131, 2021 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34874631
2.
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.
Gynecol Oncol;
186: 17-25, 2024 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38554625
3.
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.
Int J Gynecol Cancer;
34(4): 627-630, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38453176
4.
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.
Gynecol Oncol;
174: 190-199, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37210929
5.
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy.
J Natl Compr Canc Netw;
21(5): 473-479.e4, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37156482
6.
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
Br J Cancer;
127(1): 79-83, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35361918
7.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med;
381(25): 2416-2428, 2019 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31851799
8.
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Gynecol Oncol;
166(1): 36-43, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35550709
9.
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Lancet Oncol;
22(5): 632-642, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33862001
10.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Lancet Oncol;
22(2): 267-276, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539744
11.
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors".
BMC Cancer;
21(1): 1147, 2021 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34702204
12.
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
Gynecol Oncol;
163(2): 274-280, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34452745
13.
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
Int J Gynecol Cancer;
31(4): 617-622, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33318079
14.
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.
J Surg Oncol;
120(4): 786-793, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31368160
15.
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Int J Gynecol Cancer;
29(7): 1141-1147, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31420414
16.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Br J Cancer;
119(9): 1075-1085, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353045
17.
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study.
Int J Gynecol Cancer;
28(4): 729-737, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29498983
18.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol;
18(9): 1274-1284, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28754483
19.
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Int J Gynecol Cancer;
27(1): 50-58, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27749456
20.
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
Int J Gynecol Cancer;
26(5): 898-905, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27206218